PortfoliosLab logoPortfoliosLab logo
POWL vs. VRNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

POWL vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Powell Industries, Inc. (POWL) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


POWL

1D
1.46%
1M
0.75%
YTD
177.61%
6M
162.55%
1Y
372.00%
3Y*
146.47%
5Y*
94.19%
10Y*
40.56%

VRNA

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

POWL vs. VRNA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
POWL
Powell Industries, Inc.
177.61%44.49%152.21%155.62%24.34%3.60%-37.60%101.58%-9.92%-16.97%
VRNA
Verona Pharma plc
0.00%130.21%133.60%-23.92%288.84%-4.00%21.74%-40.41%-18.71%-12.07%

Correlation

The correlation between POWL and VRNA is -0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.08

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.14

Correlation (All Time)
Calculated using the full available price history since Apr 27, 2017

0.11

The correlation between POWL and VRNA shifts across timeframes, from -0.08 (1 year) to 0.15 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

POWL:

$10.77B

VRNA:

$9.72B

EPS

POWL:

$5.12

VRNA:

-$0.69

PS Ratio

POWL:

9.51

VRNA:

57.97

PB Ratio

POWL:

15.19

VRNA:

34.92

Total Revenue (TTM)

POWL:

$1.13B

VRNA:

$167.65M

Gross Profit (TTM)

POWL:

$340.78M

VRNA:

$159.52M

EBITDA (TTM)

POWL:

$236.11M

VRNA:

-$40.86M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

POWL vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

POWL
POWL Risk / Return Rank: 9898
Overall Rank
POWL Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
POWL Sortino Ratio Rank: 9898
Sortino Ratio Rank
POWL Omega Ratio Rank: 9696
Omega Ratio Rank
POWL Calmar Ratio Rank: 9898
Calmar Ratio Rank
POWL Martin Ratio Rank: 9999
Martin Ratio Rank

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

POWL vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Powell Industries, Inc. (POWL) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


POWLVRNADifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.60

Calmar ratioReturn relative to maximum drawdown

11.71

Martin ratioReturn relative to average drawdown

36.97

POWL vs. VRNA - Sharpe Ratio Comparison


Loading charts...

Drawdowns

POWL vs. VRNA - Drawdown Comparison


Loading charts...

Drawdown Indicators


POWLVRNADifference

Max Drawdown

Largest peak-to-trough decline

-73.10%

Max Drawdown (1Y)

Largest decline over 1 year

-30.88%

Max Drawdown (3Y)

Largest decline over 3 years

-55.76%

Max Drawdown (5Y)

Largest decline over 5 years

-55.76%

Max Drawdown (10Y)

Largest decline over 10 years

-68.85%

Current Drawdown

Current decline from peak

-8.45%

Average Drawdown

Average peak-to-trough decline

-36.09%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.76%

Volatility

POWL vs. VRNA - Volatility Comparison


Loading charts...

Volatility by Period


POWLVRNADifference

Volatility (1M)

Calculated over the trailing 1-month period

19.86%

Volatility (6M)

Calculated over the trailing 6-month period

44.83%

Volatility (1Y)

Calculated over the trailing 1-year period

59.91%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

64.36%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

54.84%

Dividends

POWL vs. VRNA - Dividend Comparison

POWL's dividend yield for the trailing twelve months is around 0.12%, while VRNA has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
POWL
Powell Industries, Inc.
0.12%0.34%0.48%1.19%2.96%3.53%3.53%2.12%4.16%3.63%2.67%4.00%
VRNA
Verona Pharma plc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

POWL vs. VRNA - Financials Comparison

This section allows you to compare key financial metrics between Powell Industries, Inc. and Verona Pharma plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M20222023202420252026
296.62M
75.14M
(POWL) Total Revenue
(VRNA) Total Revenue
Values in USD except per share items

POWL vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Powell Industries, Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20222023202420252026
29.7%
95.4%
Portfolio components
POWL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Powell Industries, Inc. reported a gross profit of 87.94M and revenue of 296.62M. Therefore, the gross margin over that period was 29.7%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

POWL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Powell Industries, Inc. reported an operating income of 57.58M and revenue of 296.62M, resulting in an operating margin of 19.4%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

POWL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Powell Industries, Inc. reported a net income of 45.89M and revenue of 296.62M, resulting in a net margin of 15.5%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.


Frequently Asked Questions


POWL and VRNA have a correlation of -0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for POWL and VRNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer